The initial therapeutic vaccine trials in nasopharyngeal carcinoma (NPC) patients employed autologous monocyte-derived dendritic cells (DCs) loaded with LMP2 CD8+ T cell epitope peptides. This evidence concerns the gene CD8A and nasopharyngeal carcinoma.